Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
PSTV Quote, Financials, Valuation and Earnings
Last price:
$0.28
Seasonality move
:
-8.93%
Day range:
$0.27 - $0.29
52-week range:
$0.16 - $2.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.54x
P/B ratio:
7.70x
Volume:
2.6M
Avg. volume:
14.9M
1-year change:
-76.02%
Market cap:
$38.9M
Revenue:
$5.8M
EPS (TTM):
-$1.90
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
APYX
Apyx Medical Corp.
|
$18.1M | -$0.06 | 8.07% | -17.76% | $6.00 |
|
ARAY
Accuray, Inc.
|
$100.9M | -$0.11 | -1.19% | -296.83% | $2.53 |
|
ATEC
Alphatec Holdings, Inc.
|
$212.3M | $0.04 | 20.01% | -91.85% | $24.62 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.3% | 75.74% | $104.78 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$0.28 | $5.50 | $38.9M | -- | $0.00 | 0% | 4.54x |
|
ABT
Abbott Laboratories
|
$113.29 | $133.39 | $197B | 30.59x | $0.63 | 2.12% | 4.47x |
|
APYX
Apyx Medical Corp.
|
$3.92 | $6.00 | $160.8M | -- | $0.00 | 0% | 3.28x |
|
ARAY
Accuray, Inc.
|
$0.53 | $2.53 | $60.6M | 149.00x | $0.00 | 0% | 0.14x |
|
ATEC
Alphatec Holdings, Inc.
|
$13.54 | $24.62 | $2B | -- | $0.00 | 0% | 2.76x |
|
BSX
Boston Scientific Corp.
|
$76.28 | $104.78 | $113.1B | 39.34x | $0.00 | 0% | 5.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
ABT
Abbott Laboratories
|
20.25% | 0.141 | -- | 1.12x |
|
APYX
Apyx Medical Corp.
|
87.02% | 4.899 | 48.31% | 3.58x |
|
ARAY
Accuray, Inc.
|
76.53% | 1.394 | 186.42% | 0.52x |
|
ATEC
Alphatec Holdings, Inc.
|
94.39% | 1.400 | 27.26% | 1.21x |
|
BSX
Boston Scientific Corp.
|
33.07% | 0.200 | 8.46% | 0.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
APYX
Apyx Medical Corp.
|
$5.1M | -$832K | -29.7% | -146.08% | -6.46% | -$4.1M |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | -$21.6M |
|
ATEC
Alphatec Holdings, Inc.
|
$118.1M | -$9.4M | -25.96% | -1495.13% | -4.79% | $3.1M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
Plus Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PSTV or ABT?
Abbott Laboratories has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of 15.5%. Plus Therapeutics, Inc.'s return on equity of -- beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About PSTV or ABT?
Plus Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 1843.46%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 17.74%. Given that Plus Therapeutics, Inc. has higher upside potential than Abbott Laboratories, analysts believe Plus Therapeutics, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.4 0 0 ABTAbbott Laboratories16 7 0 -
Is PSTV or ABT More Risky?
Plus Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.364% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.138%.
-
Which is a Better Dividend Stock PSTV or ABT?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.12% to investors and pays a quarterly dividend of $0.63 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PSTV or ABT?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than Abbott Laboratories's net income of $1.8B. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 30.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 4.54x versus 4.47x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.4.54x -- $1.4M -$4.4M ABTAbbott Laboratories4.47x 30.59x $11.5B $1.8B
-
Which has Higher Returns PSTV or APYX?
Apyx Medical Corp. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -15.18%. Plus Therapeutics, Inc.'s return on equity of -- beat Apyx Medical Corp.'s return on equity of -146.08%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M APYXApyx Medical Corp.39.65% -$0.05 $45.3M -
What do Analysts Say About PSTV or APYX?
Plus Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 1843.46%. On the other hand Apyx Medical Corp. has an analysts' consensus of $6.00 which suggests that it could grow by 53.06%. Given that Plus Therapeutics, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Apyx Medical Corp..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.4 0 0 APYXApyx Medical Corp.3 1 0 -
Is PSTV or APYX More Risky?
Plus Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.364% less volatile than S&P 500. In comparison Apyx Medical Corp. has a beta of 1.592, suggesting its more volatile than the S&P 500 by 59.181%.
-
Which is a Better Dividend Stock PSTV or APYX?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apyx Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Apyx Medical Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or APYX?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than Apyx Medical Corp. quarterly revenues of $12.9M. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than Apyx Medical Corp.'s net income of -$2M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Apyx Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 4.54x versus 3.28x for Apyx Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.4.54x -- $1.4M -$4.4M APYXApyx Medical Corp.3.28x -- $12.9M -$2M
-
Which has Higher Returns PSTV or ARAY?
Accuray, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -13.47%. Plus Therapeutics, Inc.'s return on equity of -- beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About PSTV or ARAY?
Plus Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 1843.46%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 372.4%. Given that Plus Therapeutics, Inc. has higher upside potential than Accuray, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Accuray, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.4 0 0 ARAYAccuray, Inc.2 0 0 -
Is PSTV or ARAY More Risky?
Plus Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.364% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.
-
Which is a Better Dividend Stock PSTV or ARAY?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or ARAY?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Plus Therapeutics, Inc.'s net income of -$4.4M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 4.54x versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.4.54x -- $1.4M -$4.4M ARAYAccuray, Inc.0.14x 149.00x $102.2M -$13.8M
-
Which has Higher Returns PSTV or ATEC?
Alphatec Holdings, Inc. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of -14.54%. Plus Therapeutics, Inc.'s return on equity of -- beat Alphatec Holdings, Inc.'s return on equity of -1495.13%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M ATECAlphatec Holdings, Inc.60.12% -$0.19 $626.3M -
What do Analysts Say About PSTV or ATEC?
Plus Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 1843.46%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 81.8%. Given that Plus Therapeutics, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Alphatec Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.4 0 0 ATECAlphatec Holdings, Inc.8 1 0 -
Is PSTV or ATEC More Risky?
Plus Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.364% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.34%.
-
Which is a Better Dividend Stock PSTV or ATEC?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or ATEC?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $196.5M. Plus Therapeutics, Inc.'s net income of -$4.4M is higher than Alphatec Holdings, Inc.'s net income of -$28.6M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 4.54x versus 2.76x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.4.54x -- $1.4M -$4.4M ATECAlphatec Holdings, Inc.2.76x -- $196.5M -$28.6M
-
Which has Higher Returns PSTV or BSX?
Boston Scientific Corp. has a net margin of -316.61% compared to Plus Therapeutics, Inc.'s net margin of 12.68%. Plus Therapeutics, Inc.'s return on equity of -- beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About PSTV or BSX?
Plus Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 1843.46%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.78 which suggests that it could grow by 37.36%. Given that Plus Therapeutics, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings PSTVPlus Therapeutics, Inc.4 0 0 BSXBoston Scientific Corp.25 0 0 -
Is PSTV or BSX More Risky?
Plus Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.364% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.
-
Which is a Better Dividend Stock PSTV or BSX?
Plus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Plus Therapeutics, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PSTV or BSX?
Plus Therapeutics, Inc. quarterly revenues are $1.4M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Plus Therapeutics, Inc.'s net income of -$4.4M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Plus Therapeutics, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Plus Therapeutics, Inc. is 4.54x versus 5.68x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PSTVPlus Therapeutics, Inc.4.54x -- $1.4M -$4.4M BSXBoston Scientific Corp.5.68x 39.34x $5.3B $670M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 21.1% over the past day.
Buy
90
TCMD alert for Feb 19
Tactile Systems Technology, Inc. [TCMD] is up 17.83% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 17.31% over the past day.
